Bokkwan Jun, MD
Neuro-ophthalmology · Flushing, NYNPI 1124256581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 60.6% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $483, 4.9 times the $98 reported in 2019.
Across 73 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$961
- Bausch & Lomb Americas Inc.$152
- Oyster Point Pharma, Inc.$72
- Argenx US, Inc.$66
- Harrow Eye, LLC$62
- ANI Pharmaceuticals, Inc.$58
- plus $214 from 6 others
What the payments were for
- Food & beverage$1,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 44 | $961 |
| Bausch & Lomb Americas Inc. | 5 | $152 |
| Oyster Point Pharma, Inc. | 4 | $72 |
| Argenx US, Inc. | 3 | $66 |
| Harrow Eye, LLC | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| AbbVie | 3 | $58 |
| Sun Pharmaceutical Industries Inc. | 3 | $46 |
| Alcon | 2 | $39 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $33 |
| Novartis | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$238
How this compares
Too few neuro-ophthalmology providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 2,502 | $1,765,084 |
| TepezzaTeprotumumab-Trbw | 12 | $518,544 |
| XiidraLifitegrast | 253 | $196,874 |
| LumiganBimatoprost | 160 | $80,680 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 609 | $31,061 |
| Alphagan PBrimonidine Tartrate | 77 | $28,655 |
| CequaCyclosporine | 48 | $27,530 |
| Cyclosporine | 66 | $18,739 |
| Prednisolone Acetate | 309 | $15,436 |
| MieboPerfluorohexyloctane/Pf | 19 | $14,574 |
| RhopressaNetarsudil Mesylate | 25 | $13,299 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 813 | $10,715 |
| Azelastine Hcl | 555 | $10,057 |
| Bepotastine Besilate | 49 | $7,971 |
| TyrvayaVarenicline Tartrate | 11 | $7,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $58 | $1,878,2142,756 claims |
| AmgenTepezza | $961 | $518,54412 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $152 | $214,457284 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $46 | $27,53048 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $13 | $13,29925 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $72 | $7,31811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuro-ophthalmology providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other neuro-ophthalmology in Flushing
- Mohammad FouladvandNew York$19K
- Mohammed UddinNew York$4K
- Manijeh ContractorAlbany$3K
- Andrew SilvermanNew York$3K
- Daniel ElefantHawthorne$969
- Erin LanzoNew York$352
- Geoffrey BassonBronx$244
- Cheng ZhangBronx$186
- Marc DinkinNew York$169
- Golnaz MoazamiNew York$140
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.